Neurent Medical raised 62.5 million euros, about $74 million, in an oversubscribed Series C announced February 11, 2026. MVM Partners led. Sofinnova Partners joined as a new investor, and EQT Life Sciences, Atlantic Bridge, Fountain Healthcare Partners and Enterprise Ireland returned. The company is based in Galway, Ireland, with U.S. operations in Braintree, Massachusetts.
NEUROMARK treats chronic rhinitis by ablating the posterior nasal nerves with impedance-controlled radiofrequency delivered through the nose. That cuts the parasympathetic signal driving mucus production and congestion. FDA cleared the system under K212666 on October 22, 2021, 60 days after receipt, and cleared the updated NMK00301 generation under K250048 in May 2025.
Commercial groundwork is already in place. A Category I CPT code for endoscopic posterior nasal nerve ablation took effect in January 2024. Cigna dropped its experimental designation in September 2025, and UnitedHealthcare expanded Medicare Advantage access in October 2025. The company's clinical results show a 55% reduction in mean reflective Total Nasal Symptom Score from baseline.
Proceeds go to U.S. commercial expansion, more clinical evidence and new indications. This is the round a device company raises after coverage arrives, when the constraint is sales headcount. The order of operations, clearance in 2021, CPT code in 2024, payer policy in 2025, is the timeline founders should budget for.